
Please try another search
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Name | Age | Since | Title |
---|---|---|---|
Frank Castellana | - | - | Member of Advisory Board |
H. Steve White | - | - | Member of Advisory Board |
William H. Koster | 81 | - | Member of Advisory Board |
Gary J. Bennett | - | - | Member of Advisory Board |
Hiroaki Masuzaki | - | - | Member of Advisory Board |
Linda R. Watkins | - | - | Member of Advisory Board |
Emilio Perucca | - | - | Member of Advisory Board |
Jiyoung Jung | 52 | 2024 | CFO & Executive Director |
Cheol-Young Maeng | - | 2023 | Member of Scientific Advisory Board |
Yung Jue Bang | - | 2019 | Chairman of the Scientific Advisory Board |
Dong Hoon Lee | 57 | 2020 | CEO, President & Executive Director |
Jacqueline A. French | - | 2023 | Member of Scientific Advisory Board |
Steve S. Chung | - | 2023 | Member of Scientific Advisory Board |
Min-Ji Kim | 53 | 2023 | Independent Director |
Yeon-Tae Kim | 53 | 2023 | Director |
Il Minn | - | 2023 | Member of Scientific Advisory Board |
Ji-Hee Suh | 63 | 2024 | Independent Director |
Yongjin Kim | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review